Life Sciences IP Litigation
We combine deep technical knowledge with best-in-class trial advocacy to protect and enforce our clients’ intellectual property
Why Cooley
-
Decades of experience resolving high-stakes disputes in the life sciences space across key jurisdictions, including Hatch-Waxman matters for branded pharmaceutical companies and complete wins in commercially significant drug ownership and licensing disputes
-
Integrated within Cooley’s renowned life sciences practice, we have significant experience in related areas, such as antitrust laws and US Food and Drug Administration (FDA) and regulatory issues, and we collaborate seamlessly with our robust patent prosecution team
-
Multidisciplinary team of industry-leading IP lawyers, including 100+ IP professionals with doctorate and master’s degrees across science and engineering disciplines
-
Unique ability to break down complex scientific subject matter to educate and persuade judges and jurors
-
Strategic pre-litigation counsel in anticipation of product launches within the context of regulatory schemes
-
More than 400 inter partes review (IPR) proceedings to date with a 70%+ institution success rate, and leading experience on both sides of US Patent Trial and Appeal Board (PTAB) proceedings
Recognition
- LMG Life Sciences: General Patent Litigation Firm of the Year – Finalist, 2024
- Chambers: Nationwide – Intellectual Property, 2024
- The Legal 500 US: Patents – Litigation (full coverage), 2024
- LMG Life Sciences: Hatch-Waxman Litigation Firm of the Year – Branded, 2024
- The American Lawyer: IP Litigation Department of the Year – Finalist, 2023
- LMG Life Sciences: Patent Strategy and Management Firm of the Year – Honoree, 2023
- Managing IP: Patent Contentious, PTAB Litigation and Life Sciences “IP Star,” 2023
They have a wide-ranging team with in-depth scientific and biotech experience, and are able to bring in experts as needed.
Chambers, 2024
